drugset
drugset / Trial / NCT00003048

Amifostine in Treating Patients With Myelodysplastic Syndrome

NCT00003048 ↗

Phase 2 Completed 12 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.

Timeline

Start
1997-06-05
Primary completion
2001-02-12
Completion
2001-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject amifostine Unknown — Intravenous

Indications

myelodysplastic syndrome